Psoriatic arthritis
Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.
The “Difficult” framework has now reached PsA. At EULAR 2025, two independent definitions were presented: one by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and another by EULAR. This short review explores the similarities and differences between these definitions and discusses their potential implications for clinical practice and research, especially for the increasingly perplexed rheumatologist.
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.

Dr. John Cush RheumNow
2 weeks 5 days ago
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb

Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis (PsO), and diagnostic delays are associated with worse prognosis, making early detection crucial. At EULAR 2025, several studies highlighted progress in prediction strategies. Here's my review of three of them.

Dr. John Cush RheumNow
2 weeks 5 days ago
EULAR 2025 – Day 2 Report
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options https://t.co/rys0pA6D6j
